Latest Organofluorides Stories
The Firm is investigating Risperdal lawsuits on behalf of men and boys who allegedly developed gynecomastia due to their use of Risperdal. New York, New York
Two New Therapies Will Match Progression-Free Survival Improvements Required By Surveyed U.S.
The Firm is representing numerous clients in Risperdal lawsuits, all of whom allegedly developed gynecomastia (male breast growth) due to their use of the atypical antipsychotic medication.
A study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 reports the results of a first-in-human, phase 1 dose escalation trial of crizotinib (XALKORI) in 14 patients with advanced, MET-amplified non-small cell lung cancer (NCT00585195).
In an aggressive disease known for poor response rates, researchers from The University of Texas MD Anderson Cancer Center found patients with advanced colorectal cancer responded well to a combination therapy of the drugs vermurafenib, cetuximab and irinotecan.
A University of Colorado Cancer Center study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) draws a line from mutation of the gene NTRK1, to its role as an oncogene in non-small cell lung cancer, to treatment that targets this mutation.
- Ceritinib achieved overall response rate of 58.5%, with a median progression-free survival of 8.2 months1 EAST HANOVER, N.J., June 2, 2014 /PRNewswire/ -- Novartis today announced data showing
Can-Fite's CF102 has FDA's Orphan Drug Designation for the treatment of advanced hepatocellular carcinoma PETACH TIKVA, Israel, June 2, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd.
Mylan will launch all strengths at earliest market formation PITTSBURGH, June 2, 2014 /PRNewswire/ -- Mylan Inc.
Phase III data for lenvatinib to be presented at ASCO WOODCLIFF LAKE, N.J., May 31, 2014 /PRNewswire/ -- Eisai Inc.
- To give a box on the ear to.